Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 83.23M | 35.33M | 2.64M | -91.99M | -105.51M |
| Total Depreciation and Amortization | 4.05M | 5.34M | 6.57M | 6.48M | 6.39M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -62.37M | -42.20M | -35.69M | 37.68M | 36.65M |
| Change in Net Operating Assets | -26.51M | -21.83M | -19.74M | -13.89M | -7.19M |
| Cash from Operations | -1.60M | -23.36M | -46.21M | -61.72M | -69.67M |
| Capital Expenditure | -835.00K | -866.00K | -312.00K | -99.00K | -- |
| Sale of Property, Plant, and Equipment | 448.00K | 589.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.51M | 12.71M | -14.04M | -26.31M | -22.16M |
| Cash from Investing | 18.13M | 12.43M | -14.35M | -26.41M | -22.16M |
| Total Debt Issued | -- | 0.00 | 0.00 | 60.07M | 60.07M |
| Total Debt Repaid | -372.00K | -372.00K | -372.00K | -43.50M | -43.13M |
| Issuance of Common Stock | 12.44M | 10.69M | 68.92M | 68.02M | 67.26M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -2.09M | -2.09M |
| Cash from Financing | 12.06M | 10.31M | 68.55M | 82.50M | 82.11M |
| Foreign Exchange rate Adjustments | 28.00K | 1.02M | 466.00K | 127.00K | 454.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.62M | 400.00K | 8.45M | -5.51M | -9.26M |